Event Overview

This 3-day forum is the “must attend” event for those senior decision-makers looking to drive their medical affairs teams and departments and enhance their KOL & stakeholder engagement at all levels.

Along with our exclusive networking dinner for all participants, the event will feature excellent networking opportunities and the chance to strengthen your contacts within the Medical Affairs community. The 2018 event was a sell-out so please make sure you book early to avoid disappointment.

Why Attend in 2019?

This event will enable you to:

  1. Understand how medical affairs are at the forefront of new pharmaceutical industry commercial models and what needs to be done to maximise success.
  2. Discover which are the most intelligent ways to map and engage with KOLs and other prescribers, payers, patient groups, pharmacies and tomorrow’s stakeholders.
  3. Measure the performance of your medical affairs team and individuals.
  4. Benchmark with experts to find out the best practices in late phase research, especially observational studies, patient registries and investigator-initiated studies.
  5. Discover how medical scientific liaisons, in support of commercial teams, are crucial to the communication of effectiveness, safety and cost effectiveness.
  6. Learn how the medical affairs role can engage KOLs & enhance value for medical devices due to their unique product lifecycle and characteristics.
  7. Get real-life experiences of medical affairs capabilities development in smaller Pharma, Biotech & MedTech companies.

Speakers List

Industry experts: Large & Medium Pharma

Bruce Lavin

Vice President and Head of External Engagement & Policy
Neurology Patient Value Unit
UCB, USA

Ghiesla Nel

Head of Global Medical Information
Ipsen Pharma, UK

Vice President, Global Medical Affairs Head, Respiratory
Sanofi-Genzyme

Medical Excellence Director, Region Europe
Novartis Oncology

VP, Medical Affairs, Norgine
Excellence Lead, Pinnacle Wellbeing Services, UK

Senior Director, Enterprise Benefit Risk Medical Director
Worldwide Medical and Safety | Global Medical Impact Assessment
Pfizer, USA

Andrzej Smyk

EMEA Medical Affairs Director
Merck Group, Poland

Ruth Duffy

Senior Medical Director
US Medical Affairs Lead – Neuroscience
Otsuka Pharmaceutical Development and Commercialization, USA

Kumaran Krishnan

Medical Director, Region Europe, MSL and Digital Transformation
Teva

Rafia Bhore

Director, Biostatistics
Celgene, USA

Piotr Wlodarczyk

General Medicine Clinical Director European Clinical Development Team
MSD, Poland

MSL Manager
Janssen, Pharmaceutical Companies of Johnson and Johnson, UK

Ulf Hengstmann

Digital Health Innovation Manager
Bayer Business Services

Partner
McKinsey & Co., Switzerland

Industry experts: Smaller Pharma, Biotech & MedTech

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

Consultant, R&D
BTG International, UK

Senior Director, Global Medical Science Liaison
Philips, USA

Tobias Suiter

Vice President Medical Affairs
Pharming Group, Netherlands

Ondrej Novak

Medical Director CEEMERIT
Kyowa Kirin Pharma, Czech Republic

Elizabeth Pash

Vice President Medical Affairs
Gelesis, USA

Adam Jones

Head of Medical Affairs, International
ViiV Healthcare, UK

Peter Shaw

Chief Medical Officer, Surgical Products & Exogenous
Bioventus, USA

External Stakeholders

Vincenzo Costigliola

President
European Medical Association, Belgium

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Alex Wyke

CEO
Patient View, UK

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

Experienced Solution Provider

Senior Vice President, Business Partnerships
Within3

CEO, Head of Clinical Services, Senior Executive Coach
Pinnacle Wellbeing 247

Executive
Vynamic, UK

Director
PharmaReview, UK

Angela Rylands

Principal Consultant Patient Centred Outcomes
Open Health, UK

Event Structure

Photo Gallery

Event Program

MedAffairs Strategic Capability Development

Day 1 - 26th February, 2019

Stream Overview

The first day will feature several keynote presentations from VP-Level thought leaders on shaping and leading the medical affairs departments, justifying medical affairs performance through innovative metrics and tracking effectiveness of the function as an essential element of today’s pharmaceutical companies. They will be discussing the strategic drivers for medical affairs, and guidance on how to make best use of this vital function.

08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks
09.10
Capturing competitive advantage through Medical Capabilities
  • Which capabilities should Medical Affairs leaders prioritise for success?
  • How medical team compositions are changing in today’s environment
  • The growing importance of digital & agile capabilities

Partner
McKinsey & Co., Switzerland

09.40
Mapping and engaging with new and more influential KOLs
  • The role of medical affairs today in comparison to 5-10 years ago.
  • Which KOLs are more influential today?
  • How to map & engage with these new KOLs: which new medical affairs capabilities are needed?
  • USA & Europe: differences & similarities.
  • Lessons learned.
Bruce Lavin

Vice President and Head of External Engagement & Policy
Neurology Patient Value Unit
UCB, USA

10.20
Insight development as a value driver for medical affairs

Senior Director, Global Medical Science Liaison
Philips, USA

10.40
Networking & Coffee Break Sponsored by: Within3
11.10
Creating & managing cross-functional teams: Best practices of medical affairs interaction with internal stakeholders
Ghiesla Nel

Head of Global Medical Information
Ipsen Pharma, UK

11.40
Enhancing the Medical team's role and influence in product launch & lifecycle
  • The Medical Affairs team plays an integral role in the full lifecycle of product development.
  • Medical Affairs collaborates across functional groups to help prepare the medical community in anticipation of a new product .
  • All functional groups within medical affairs have responsibilities during product launch preparation.
  • Medical affairs must play a strategic role in lifecycle management decisions as the product matures.
Ruth Duffy

Senior Medical Director
US Medical Affairs Lead – Neuroscience
Otsuka Pharmaceutical Development and Commercialization, USA

12.20
Panel discussion: The Impact of internal stakeholders on medical affairs capabilities development
  • Managing cross functional teams i.e. clinical/ regulatory/commercial /market access.
  • Which skills are required from medical affairs professionals today in order to co-operate with internal stakeholders?
  • Unique medical affairs HR plans for talent recruitment and retention.
Ruth Duffy

Senior Medical Director
US Medical Affairs Lead – Neuroscience
Otsuka Pharmaceutical Development and Commercialization, USA

Consultant, R&D
BTG International, UK

Tobias Suiter

Vice President Medical Affairs
Pharming Group, Netherlands

Ghiesla Nel

Head of Global Medical Information
Ipsen Pharma, UK

13.00
Luncheon Break
14.00
Leveraging online discussion platforms for optimal stakeholder engagement
  • Identify the logistical and resource barriers to domestic and global stakeholder engagement 
  • Learn about innovative communication solutions that leading organizations utilize to overcome these challenges 
  • Discuss how to use these solutions to deliver improved engagement outcomes while maintaining regulatory compliance

Senior Vice President, Business Partnerships
Within3

14.30
Recruiting the future medical affairs professionals: Which digital skills are needed?

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

EXTERNAL STAKEHOLDERS’ PERSPECTIVE

15.00
The role of technology and pharmaceuticals in delivering care today & tomorrow
Physicians’ Perspective
Vincenzo Costigliola

President
European Medical Association, Belgium

15.30
Networking & Coffee Break Sponsored by: Open Health
16.00
Increasing the efficiency of your Medical Affairs Team: The Silent Time Killer of Copy Review
  • Case Study: How outsourcing can unburden your team to focus on
    value-adding relationships

Director
PharmaReview, UK

16.30
Engaging Patients in pharmaceutical R&D
Patients’ Perspective
Alex Wyke

CEO
Patient View, UK

17.00
Actionable approaches to driving Medical Affairs effectiveness
  • Decision-making to create simplicity
  • Implementation of strategic frameworks
  • Organizational culture and performance in Medical Affairs

Executive
Vynamic, UK

17.30
Panel discussion: Optimising cooperation with external stakeholders: Understanding their expectations and requirements
  • Understanding external stakeholders’ new requirements.
  • How can the pharma industry satisfy them all?
  • How does this affect medical affairs goals, definitions and structure?
Bruce Lavin

Vice President and Head of External Engagement & Policy
Neurology Patient Value Unit
UCB, USA

Vincenzo Costigliola

President
European Medical Association, Belgium

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Alex Wyke

CEO
Patient View, UK

Senior Director, Global Medical Science Liaison
Philips, USA

18.20
Chairperson’s closing remarks
18.30
End of day one

19.00 - Exclusive Networking Dinner for Event Participants

Real-World Evidence Generation for MedAffairs

Day 2 - Stream 1 - 27th February, 2019

Stream Overview

Generating real world evidence via observational studies and the use of patient registries is one of the fastest growing areas of pharmaceutical R&D. Such post-marketing studies are becoming increasingly important as regulatory agencies demand more long-term data which demonstrates efficacy, safety and quality. The Medical Affairs unit plays a decisive role in generating this vital evidence and this stream will present solutions to the challenges companies face in generating high-quality evidence which will communicate a compelling value argument to all necessary stakeholders.

08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks

REGULATOR & PAYER VIEWS

09.10
Payer RWE needs: What drives payers’ reimbursement considerations?

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

09.50
Bridging the gap between late-phase clinical trials and RWE
  • What can be done to narrow the gap between clinical studies and RWE?
  • Which internal stakeholders are involved, what are their needs and can we satisfy them all in Phase III and IV trials?
  • How can we work better with external stakeholders to achieve this?
Piotr Wlodarczyk

General Medicine Clinical Director European Clinical Development Team
MSD, Poland

10.30
Clinical evidence for next-generation products: New thinking
  • Collecting clinical outcomes following product registration in a real-world setting.
  • Harnessing technologies to handle clinical data throughout the product life cycle.
  • Persuading stakeholders to embrace the changing paradigm.

Consultant, R&D
BTG International, UK

11.10
Networking & Coffee Break
11.40
How will Patient Centred Outcomes enhanced your evidence strategy
Angela Rylands

Principal Consultant Patient Centred Outcomes
Open Health, UK

12.20
Generating RWE through social media and other digital platforms

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

13.00
Luncheon Break
14.00
Application a semi-automatic handling of adverse events in digital enhanced clinical trials
Ulf Hengstmann

Digital Health Innovation Manager
Bayer Business Services

14.40
The medical department's role in managing the product's lifecycle

Vice President, Global Medical Affairs Head, Respiratory
Sanofi-Genzyme

15.20
Networking & Coffee Break
15.50
Panel discussion: Leveraging real-world evidence to make a meaningful difference to your product value
  • Demonstrating the ROI of RWE to internal stakeholders.
  • Strategies for small/medium pharma to generate RWE on limited budgets.
  • Motivating academically-focused investigators for commercially-focused studies.
  • Incorporating HEOR endpoints into Phase III and IV studies.
  • Integrating IIT into your post-marketing development strategy.
  • The increasing impact of eHealth, AI and big data.

Vice President, Global Medical Affairs Head, Respiratory
Sanofi-Genzyme

Piotr Wlodarczyk

General Medicine Clinical Director European Clinical Development Team
MSD, Poland

Consultant, R&D
BTG International, UK

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

Ulf Hengstmann

Digital Health Innovation Manager
Bayer Business Services

16.40
Chairperson’s closing remarks
16.50
End of day two

Enhancing Medical Communications & Liaison

Day 2 - Stream 2 - 27th February, 2019

Stream Overview

Medical Affairs departments are increasingly looking to implement next generation medical communication practices, to offer essential evidence-based information to stakeholders on demand, through a variety of classical, yet also increasingly digital channels. This stream will focus on two key aspects of medical communication. Firstly, issues such as: protocol writing for internal late-phase studies and research initiatives; working with External Experts (KOLs) to enhance publications, abstracts & posters and receiving proposals for investigator-initiated studies. The second section of this day will focus on Medical Scientific Marketing communications, including the review process, compliance issues, ensuring the claims made by marketing colleagues are justified and appropriately communicated and also effectively localized from global-level to country-level market requirements. The day will also feature best practice case studies on structuring, managing, and monitoring the evolving Medical Science Liaison role within your organisation. This meeting is an ideal chance to benchmark with other market leaders in this field who are utilising the unique MSL function to more effectively communicate with external experts, engage them with advanced science and demonstrate product evidence. All attending will discovery how MSLs can help regain the credibility of the pharmaceutical industry as a value-adding partner to the healthcare ecosystem.

08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks
09.10
Unlocking the value of medical through communication skills
  • Overview of communication skills. What really matters?
  • Managing, developing and training communication soft skills.
  • Examples of how soft skills are increasing the value of medical affairs and learnings from other markets.

Medical Excellence Director, Region Europe
Novartis Oncology

09.50
Communicating medical benefit risk assessments to patients, healthcare providers and other stakeholders

Senior Director, Enterprise Benefit Risk Medical Director
Worldwide Medical and Safety | Global Medical Impact Assessment
Pfizer, USA

10.30
Utilizing scientific data to support publications and abstracts of investigators KOLs/External Experts
Rafia Bhore

Director, Biostatistics
Celgene, USA

11.10
Networking & Coffee Break
11.40
Patients as stakeholders in Medical Affairs

As end-users of medicines and devices, patients and carers are our ultimate stakeholder.  The advent of digital technology is changing the paradigm of communication between patients, Pharma and MedTech. This talk explores the evolution of patient engagement, and the role of Medical Affairs as a catalyst for the development of productive relationships in this space.

CEO, Head of Clinical Services, Senior Executive Coach
Pinnacle Wellbeing 247

VP, Medical Affairs, Norgine
Excellence Lead, Pinnacle Wellbeing Services, UK

13.00
Luncheon Break

MSL CAPABILITIES, MANAGEMENT & TRAINING BEST PRACTICES

14.00
MSL’s and Medical Communication during pre-launch activities
  • Between Clinical Development and marketing authorisation
  • Waiting for a product and reimbursement
  • Complexity of a cross-functional cooperation
Andrzej Smyk

EMEA Medical Affairs Director
Merck Group, Poland

14.40
Should we have targets for customer-related activities for MSLs?
  • Findings of a primary research
Kumaran Krishnan

Medical Director, Region Europe, MSL and Digital Transformation
Teva

15.20
Networking & Coffee Break
15.50
Upskilling a 400 colleagues EMEA MSL Function – a Janssen success story
  • Identification of priority areas.
  • Development of program.
  • Implementation of program and impact.

MSL Manager
Janssen, Pharmaceutical Companies of Johnson and Johnson, UK

16.30
Panel discussion: Next generation MSL capability development
  • Which new capabilities are required from MSLs today and will be in the future?
  • What has to change internally to enable MSL success?
  • The emerging importance of health outcomes liaison.
  • Capabilities and reskilling training.

Medical Excellence Director, Region Europe
Novartis Oncology

Senior Director, Enterprise Benefit Risk Medical Director
Worldwide Medical and Safety | Global Medical Impact Assessment
Pfizer, USA

Andrzej Smyk

EMEA Medical Affairs Director
Merck Group, Poland

Kumaran Krishnan

Medical Director, Region Europe, MSL and Digital Transformation
Teva

Rafia Bhore

Director, Biostatistics
Celgene, USA

17.20
Chairperson’s closing remarks
17.30
End of day two

MedAffairs Effectiveness for Smaller Companies

Day 3 - Stream A - 28th February, 2019

Stream Overview

  • Building an effective, medical affairs team with limited resources, that adds-value to external stakeholders
  • Determining what capabilities, skills, resources and team structure is realistically required to maximise performance
  • Cultural change: Transformation to a patient and stakeholder-centric organization, that is science-led.
  • Maximisation of real-world evidence generation on limited budgets
  • Leveraging both classical and digital medical communication strategies with a small team to maximise dialogue with KOLs and stakeholders
  • Demonstrating the value of medical affairs to internal stakeholders
08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks
Tobias Suiter

Vice President Medical Affairs
Pharming Group, Netherlands

09.10
Designing the medical affairs team in a smaller organisation
  • Which unique skills are we looking for?
  • How to measure performance in a smaller organisation?
  • Driving a cultural change in the company
Tobias Suiter

Vice President Medical Affairs
Pharming Group, Netherlands

09.50
Medical affairs in diagnostics: How different is it?
  • Building a medical affairs team in diagnostics.
  • Is a different skill set needed?
  • Delivering medical value in diagnostics.
  • Working together with pharma.

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

10.30
MSL performance measurement in a smaller organisation: How to make sure that the team is contributing to business in an ethical manner?
Elizabeth Pash

Vice President Medical Affairs
Gelesis, USA

11.10
Networking & Coffee Break
11.40
The added value of Investigator Initiated Trials (IITs)
  • What is the added value of IITs in comparison to large industry initiated studies?
  • Doctors helping doctors to solve medical problems: How does it work in reality?
  • Which other external stakeholders are benefiting from IITs?
  • What is the contribution of IITs for product lifecycle and other company goals?
Peter Shaw

Chief Medical Officer, Surgical Products & Exogenous
Bioventus, USA

12.20
Creating a high-performing medical team from scratch
  • Ideal department structure and reporting lines.
  • Which skills are required from medical affairs professionals today in a small / medium pharma Company?
  • Implementing personality tests in the recruitment process
  • Lessons learned, next steps.
Ondrej Novak

Medical Director CEEMERIT
Kyowa Kirin Pharma, Czech Republic

13.00
Luncheon Break
14.00
Panel Discussion: Capabilities development for smaller pharma, biotech & MedTech
  • What is the ideal role of the medical affairs department today in a dynamic cross functional team?
  • How to build a high-performance team with limited resources?
  • Establishing communications and new value-adding relationships.
  • Ideal department structure and reporting lines in smaller corporations.
  • Demonstrating the value of medical affairs to internal stakeholders in a smaller organisation.

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

Tobias Suiter

Vice President Medical Affairs
Pharming Group, Netherlands

Elizabeth Pash

Vice President Medical Affairs
Gelesis, USA

Adam Jones

Head of Medical Affairs, International
ViiV Healthcare, UK

14.50
Chairperson’s closing remarks
15.00
End of day three

Interactive Workshop: Charisma Masterclass for MedAffairs Executives

Day 3 - Stream B - 28th February, 2019

Stream Overview

The industry-leading ‘Charisma Masterclass for Medical Affairs Executives’ is the top personal effectiveness training program. It helps senior executives to uncover and utilize their latent inner power.

The Charisma Masterclass is uniquely tailored for entrepreneurs, business leaders and high potential professionals. Participants will learn to fast track ability to create the perfect first impression and to optimize each and every interaction. Register now and learn how to influence, persuade, and inspire.

08.30
Registration & Coffee
09.00
Interactive Workshop: Charisma Masterclass for Medical Affairs Executives

By the time you have completed this course, you will have learnt how to:

  • Develop your personal presence
  • Deepen your rapport with others
  • Achieve self-mastery of thought and emotion
  • Hone your negotiation and persuasion skills
  • Earn the trust of others
  • Diffuse conflict effortlessly
  • Actualize your body language and vocal skills to elevate your personal brand
  • Consistently be the best version of yourself
  • Really live in the here and now

CEO, Head of Clinical Services, Senior Executive Coach
Pinnacle Wellbeing 247

VP, Medical Affairs, Norgine
Excellence Lead, Pinnacle Wellbeing Services, UK

17.00
End of Day Three
One to one micro coaching sessions:
Experience the benefits of coaching in a 30 minute one to one ‘micro coaching’ session with one of Pinnacle Wellbeing Services experienced coaches.  We can help you work through a current issue, plan next steps with a project, goal or objective or simply step back and consider how to bring the best possible you to work. Pre-booking necessary.

PHARMA & MEDICAL DEVICE: VPs, Directors & Managers of:
Customer Relations, Medical Affairs, Medical Science Liaisons, Medical Education, Health Outcomes & Liaison, Medical Communications,
Marketing, KOL & Stakeholder Engagement, Late Phase & Real-World Research, Scientific Affairs, Medical Advisors and Patient-Centricity.

Platinum Event Partner

Event Partners

Media Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Speaker Biographies

Paul Rowe

Vice President, Global Medical Affairs Head, Respiratory
Sanofi-Genzyme

Dr. Rowe has well over a decade of research experience spanning from pre-clinical to late phase drug development programs, primarily in respiratory (and cardiovascular) medicine.He has been directly responsible for medical strategy and lifecycle management of several Chronic Obstructive Pulmonary Disease (COPD), asthma,thrombosis, and cardiovascular medicines. Dr. Rowe has been successfully involved in achieving New Drug Application (NDA) approvals for first in therapeutic class respiratory products and also has led various clinical development global projects from phase II through phase IV clinical trials.            

He has authored and co-authored several publications in respiratory medicine (COPD-focused, and is a frequent lecturer and speaker at professional society meetings, and educational forums.Dr. Rowe holds degrees from Harvard University and the University of Rochester School of Medicine, and certifications from the London School of Economics and Villanova University.

Dr. Rowe is an active member of several national and international societies and he recently served as Vice Chair of the Drug, Device, Discovery, and Development Committee of the American Thoracic Society (ATS)and has received the distinction of being named a ATS Fellow.               He has a primary interest in promoting international medical research collaboration and innovation across government, academia, and industry.

In his current role, Dr. Rowe is responsible for building and leading a Global Medical Affairs team and strategy within the respiratory space for several novel compounds in mid and late stage development, in various therapeutic indications.

Andres Stern

Medical Excellence Director, Region Europe
Novartis Oncology

Andres Stern is the Region Europe Medical Excellence and MSL Director in Novartis Oncology. He has 10 years’ experience in the pharmaceutical industry in different roles such as Medical Advisor, MSL Manager and Therapeutical Area Head. Prior joining Novartis he served in Wyeth in Rheumatology and in Grunenthal Pharma dedicated to Pain.

Andres was born in Buenos Aires, Argentina in 1976 and lives in Spain since 2005. Since 2017, he joined the Region Europe HQ in Milan. He holds a medical degree from maimonides university, Argentina.

In his current position Andres leads and coordinates a team of over 160 MSLs across Europe and his focus areas are Breast Cancer, Melanoma, Lung Cancer and Hematological malignancies.

Liz Clark

VP, Medical Affairs, Norgine
Excellence Lead, Pinnacle Wellbeing Services, UK

Liz Clark is a pharmaceutical physician with over 20 years’ experience in the Pharmaceutical Industry.  Having qualified in Medicine at Imperial College London, she undertook 4 years of general medicine prior to joining the pharmaceutical industry.  She has held both office and field based roles in Medical Affairs, Marketing and Sales Management, working with both medicinal products and devices.  She is currently Vice President of Medical Affairs at Norgine Ltd. where she also responsible for leading Norgine’s patient engagement work.  Liz is passionate about personal development, management and leadership skills.  She is a qualified business coach and appraiser for the Faculty of Pharmaceutical Medicine, and has recently started to deliver business training and coaching for Pinnacle Wellbeing Services alongside her work at Norgine.

Annlouise R. Assaf

Senior Director, Enterprise Benefit Risk Medical Director
Worldwide Medical and Safety | Global Medical Impact Assessment
Pfizer, USA

Dr. Annlouise Assaf is a pharmacoepidemiologist who is Senior Director and Enterprise Benefit Risk Medical Director in the Global Medical Impact Assessment group at Pfizer.  In this role, she partners to evolve the science and practice of Benefit Risk to inform better outcomes for patients, drug development, and healthcare decisions. A focus of her work is on quality benefit risk communication and improving health literacy and patient-centered medication prescribing so that patients can make informed shared decisions about their treatment, use their medications safely and appropriately, and improve value outcomes. Dr. Assaf is also a co-lead on the Health Literacy Working Group at Pfizer. Dr. Assaf joined Pfizer in 2002 after many years in academic medicine and clinical research at Brown Medical School.  She received her doctorate from the Roswell Park Cancer Institute in Buffalo where she
focused her research efforts in the field of cancer and cardiovascular disease epidemiology with a particular focus on diseases which disproportionately affect women and patients with low health literacy.   

Dr. Assaf was Co-Principal Investigator of the Pawtucket Heart Health Program, a community-based intervention for prevention of cardiovascular disease, where she specialized in the evaluation of programs aimed at behavior change in low health literacy, low income, and minority populations.  Dr. Assaf has been Principal or Co-Principal Investigator for numerous NIH clinical trials.  She was a Principal
Investigator and Executive Committee Member of the Women’s Health Initiative (WHI) Clinical Trial and Observational study and ran the largest of the 40 clinical centers of WHI. She has served in numerous teaching, consulting, and leadership roles nationally and internationally and is currently a Professor (Adjunct) at The Brown University School of Public Health. She has published over 100 scientific articles, book chapters, and abstracts.

Fernando Orden Rueda

MSL Manager
Janssen, Pharmaceutical Companies of Johnson and Johnson, UK

Fernando is the Oncology MSL Manager of Janssen UK. In his role, he is responsible for providing leadership, coaching, guidance and development of his MSL team and the overall UK MSL function. He is also a member of the strategic, cross-functional oncology leadership team in the UK. Previous to this role, Fernando was the Janssen Europe Middle East and Africa (EMEA) Medical Affairs Strategic Projects Manager, where he drove a cross-functional team to successfully develop and implement an ambitious strategic programme to upskill and develop Janssen’s 400+ MSLs and MSL Managers workforce across EMEA.

 

Fernando has a BSc + MSc in Biotechnology from Salamanca University (Spain) and Melbourne University (Australia) and a MRes in Genetic Medicine from the University of Manchester. He has worked in cancer research in academia in Spain and in the Breakthrough Breast Cancer Group at Cancer Research UK. He also worked in AstraZeneca in R&D as a research scientist in the Oncology Pre-Clinical Development and Oncology Precise Medicine teams. Before joining Janssen, he was awarded a full merit scholarship to study Management at London Business School.

Alexandra Zemp

Partner
McKinsey & Co., Switzerland

Alexandra Zemp is Partner with McKinsey. She is co-leading McKinsey’s Medical Affairs practice in Europe with a specific focus on capability building. Beyond that, her Medical Affairs work spans from designing Medical Affairs organizations, over defining Medical Affairs strategies, to defining & implementing digital innovation in Medical Affairs, such as advanced analytics on real world data.

Albert Jan Schutte

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

AJ qualified as an MD at the Free University of Amsterdam (NL) and worked several years in Internal Medicine in Amsterdam. In 2008 he joined Roche in Basel from Schering-Plough/Organon in New Jersey
to take over the leadership of the Ocrelizumab Multiple Sclerosis
Life Cycle team. In February 2013 he was appointed Therapeutic
Area Head Medical Affairs Neuroscience/Cardio-Metabolism and
in October 2015 he took the opportunity to build and lead the Medical Affairs Team at Roche Diagnostics in Rotkreuz. He started his career in Pharma as a Medical Advisor CNS with Solvay Pharma in the Netherlands working in Depressive and Anxiety Disorders. After several years of operational work at the affiliate level he joined Solvay
Pharma International as Medical Manager Middle East and Asia Pacific. In 1998 he joined Organon International where he predominantly worked in Neuroscience (depression, bipolar disorders, schizophrenia) and developed experience across the value chain being involved in Strategy Development from Proof of Concept to the implementation of Medical Strategy at affiliate level. In 2002 he joined the US Headquarters where he was Executive Director Neuroscience, both as Global Marketing Director and Global Medical Affairs Lead.

Nermeen Varawalla

Consultant, R&D
BTG International, UK

With a background in academic clinical medicine Nermeen is an experienced business leader who has founded, grown and exited from global life sciences businesses in start-up and corporate settings. She is a recognised expert and thought leader in the clinical development of pharmaceuticals and medical devices. With a strong interest in innovative and pragmatic approaches for the generation of clinical evidence to enable adoption of new treatments, Nermeen is developing BTG’s approach for utilising big data technologies including AI and Real World Evidence for the assessment of clinical outcomes.

Dr Varawalla completed her undergraduate and specialist medical training at the University of Mumbai, before receiving a Rhodes Fellowship to the University Oxford where she obtained her doctorate from the Institute of Molecular Medicine. She is a Fellow of the Indian College of Physicians & Surgeons and a Member of the Royal College of Obstetrics and Gynaecology.

As a SYLFF fellow, Nermeen completed an MBA at INSEAD, following which she worked at Accenture’s Strategy Consulting Practice. Since then she has worked in the clinical development industry with contract research organisations, pharmaceutical and medical device companies. She serves as a Trustee of the Malaria Consortium.

Kevin Appareti

Senior Director, Global Medical Science Liaison
Philips, USA

Kevin Appareti is Senior Director, Global Medical Science Liaison in the Chief Medical Office at Royal Philips.  He leads the Key Thought Leadership Program and works across Philips’ businesses, markets, and research to build strong internal and external relationships with key thought leaders and influencers.  Kevin partners with internal business, market, and research leaders to develop strategic Key Thought Leader (KTL) engagement programs to deliver strategic guidance, leverage clinical and scientific knowledge, foster peer-to-peer relationships, and support clinical and marketing evidence development in support of Philips meaningful innovations.

Prior to the 7 years he has been in the Chief Medical Office, he had 25 years of experience in the Ultrasound Business Unit where he held a variety of leadership positions. He was senior marketing manager of the global luminary program where he contributed to establishing a structured approach to thought leader management. He was also worldwide market development manager and director of product marketing for cardiovascular ultrasound where he brought to market many cardiovascular ultrasound products that set the standard in performance and reliability.  He has held additional positions in marketing management for profes­sional services, information technologies and clinical marketing.

He began his academic, research and clinical career as Program Director for Diagnostic Medical Ultrasound Education at the University of Colorado Health Sciences Center where he was involved in clinical research in fetal echocardiography, neonatal brain imaging, and ultrasound technology assessment.  He has co-authored many scientific papers, book chapters and presented at numerous international scientific conferences.

He then moved to industry with various clinical and management roles with Hewlett Packard, Agilent Technologies, and now Royal Philips.  Kevin holds a bachelor’s degree in physical science from Colo­rado State University and an MBA from Boston University and has been an adjunct professor at the University of Massachusetts at Lowell, Manning School of Business.

Kevin is married and has 4 boys.  He enjoys basketball, road cycling, tennis and he is an avid photographer.

Diar Fattah

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Diar is the Associate Director of Medicines Optimisation at Dartford, Gravesham and Swanley and Swale CCGs. Diar takes the lead on the provision of medicines optimisation on all matters relating to medicines use, prescribing and the provision of pharmaceutical services to the CCGs. His interests have been focused on combatting inappropriate polypharmacy with the use of healthcare data analytics.

Diar also sits on the NICE technology appraisal committee, analysing HTA applications for the NHS.

Previously, he has worked as Medicine Optimisation Pharmacist at Medway CCG, a tutor at the Centre for Pharmacy Postgraduate Education (CPPE) based at the University of Manchester and a pharmacist clinical advisor in NHS 111.

Diar holds a Masters in Pharmacy and a Masters in Health Economics and Health Policy."

Isabelle Hilali

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

Isabelle Hilali is CRI - Center for Research & Interdisciplinarity’s Managing Director. CRI is a unique place that experiments and spreads new ways of learning, teaching, conducting research and mobilizing collective intelligence in life, learning and digital sciences. She is also Board Member of the Healthcare Data Institute, a think tank, that gathers
a large community of big data and health experts. As a true and positive leader, she is a dedicated professional committed to the health and education fields. Before joining CRI, Isabelle held several senior management positions in the eHealth field as well as in the mobile and internet industry, both in France and internationally. She holds a Masters
degree from “Institut d’Etudes Politiques (Sciences Po) de Grenoble” and “Université Paris I - Panthéon Sorbonne” in Military Strategy.

Peter Gannon

Senior Vice President, Business Partnerships
Within3

With more than 18 years diversified experience in the life sciences vertical, Peter has been involved in digital pharmaceutical communications since 1996. His leadership in strategic planning, revenue generation, and business partnering has established a strong and diverse client-base for Within3. His expertise and experience in working closely with organizations to adopt new technologies proves invaluable to clients and partners as they adopt new solutions. His consultative demeanor and willingness to work collaboratively continually provides benefits to clients and partners old and new as Within3’s business grows and evolves.

 

As part of the leadership team for Hyphen, an Omnicom-owned digital agency, Peter developed and implemented strategies that established Hyphen’s market presence, grew product offerings, and drove business development and customer acquisition. Hyphen grew exponentially from 2003 to ­2007, quadrupling staff and revenues while acquiring new clients and opportunities annually. Peter has also held positions with Sermo, Peer Direct, Torre Lazur, and Commonhealth developing business and leading accounts. Peter has worked extensively across the industry resulting in successful innovation for clients and healthcare professionals alike.

Richard Reid

CEO, Head of Clinical Services, Senior Executive Coach
Pinnacle Wellbeing 247

Richard’s early career was as a Senior Consultant for a major multi-national business consultancy. This enabled him to observe and experience first-hand workplace issues such as management culture, stress and conflict.

His core areas of expertise include Emotional Intelligence and Resilience. Richard coaches C-Suite leaders on themes such as Charisma and Conscious Leadership, as well as helping management teams to work more effectively towards common goals and objectives.

As a practicing coach and qualified psychologist, he has advised organisations such as Google, PwC, KPMG, Ernst & Young, Cap Gemini and Reckitt Benckiser.

Richard is also recognised by the media where he is often asked for expert commentary, having appeared on Sky 1, BBC, Bloomberg, and Radio 5Live.

Gemma Pfister

Executive
Vynamic, UK

Gemma is an Executive with Vynamic, a Healthcare Industry Management Consulting company that approaches healthcare as five interwoven sectors. Gemma has more than 20 years of Healthcare experience, with a major focus on Global Medical Affairs. Her interests are in partnering with clients to design and implement strategic frameworks, business processes, and operating models that complement the evolving priorities of pharma and biotech organizations.

Tessa Pugh

Director
PharmaReview, UK

Tessa graduated with a degree and professional diploma in Strategic Marketing in the early 1990s. Her formative years were spent in client facing roles at advertising agencies, including Saatchi and Saatchi and FCB in London, where she looked after Financial Services and FMCG clients. Tessa launched PharmaReview 7 years ago, with Dr Ralph Carter.  PharmaReview is a   specialist provider of outsourced copy review services to the pharmaceutical industry.  Its  mission is to reduce the time and cost which internal copy review places on senior members of  clients’ medical, regulatory and commercial teams while maintaining the highest levels  of regulatory adherence and compliance. Tessa is a highly experienced practitioner in ZincMAPS and Veeva Vault PromotMats functionaility and a copy review process expert.

Previous Attendees at MedAffairs Leaders Forum - London, UK, 2018

Company
Job Title
Abbvie
Medical Unit Lead Gastroenterology
Abbvie
Associate Director
Air Liquide Santé International
Medical Affairs Director, World Business Line
Alere
EME Medical Director
Alere
European Director of Clinical Affairs
Amgen
Executive Medical Director
Astellas
National Director – Health Economics & Outcomes Research Medical Affairs, Americas
Bayer AG
Medical Affairs Physician
Biocompatibles UK Ltd, a BTG International group company
SVP Head Clinical Development
Bristol-Myers Squibb
Head of Cardiovascular Development - Therapeutic Area Head
Bristol-Myers Squibb
Medical Strategy, Operations & Governance Lead
Celgene
Associate Director Medical Affairs
Celgene
Senior RML Manager
Chiesi
Global Medical Affairs Director
Chiesi
Medical Manager
Chugai
Medical Director
Chugai
Head of Medical Affairs
Cisiv Ltd
Commercial Director
CK Clinical
Medical Manager
CK Clinical
Senior Consultant
Complete HealthVizion
Scientific Director
Complete HealthVizion
Director of Scientific Services
Costello Medical
Senior Analyst
Costello medical
Analyst
Covance
Senior Director, Market Access & Medical Affairs
Covance
Senior Director, Medical Affairs & LCM
EMA Committee on Advanced Therapies (CAT)
Alternate Patient member
Envision Pharma Group
Chief Strategy Officer
EUSA Pharma
Head of Global Oncology medical Affairs
Genentech
Lead, National Managed Care Liaisons, PACE (Patient Access Collaboration and Exchange), US Medical Affairs
Genetic Alliance
Director, Genetic Alliance, UK Member, NHS England Rare Diseases Advisory Group
GlaxoSmithKline
Director of Global MSL Practices & Medical Training
GlaxoSmithKline
SVP, Head Worldwide Medical Affairs
GlaxoSmithKline
Vice President Global Head of Selling Excellence
GN Hearing
Director of External Relations
H. Lundbeck A/S
Senior Manager Medical Affairs
HealthCore
President
Helsinn Healthcare
Head of Medical Affairs
Helsinn Healthcare
Medical Affairs Manager
IBM Watson Health
Deputy Chief Health Officer, Watson Health
IBM Watson Health
Vice President, Outcomes Research
ICTA PM
Business Development
Jazz Pharma
VP and Head of Medical Affairs EU/RoW
Kantar Health
Senior Director
Kantar Health
Director, Client Consulting
Kantar Health
Client consultant, Real World Evidence – Europe
Kantar Health
Director Client Management
Kantar Health
Marketing business Partner APMEA
Kyowa Kirin
International Medical Affairs Director
Kyowa Kirin
International Medical Affairs Manager
Kyowa Kirin
Scientific Director
Kyowa Kirin
Medical Manager
LEK-AM Pharmaceutical Company
Medical Advisor
Luminex Corporation
Senior Director, Global Scientific Affairs
Medicines for Europe
Market Access Director
Medineos
Real World Data Advisor
Medineos
Managing & Scientific Director
MONOCL AB
Sales Director
MSD France
MSL manager
MSD France
MSL Acute Care
Mundipharma Pharmaceuticals
Medical Director
Norgine
EU Medical Director
Novartis Pharma
Regional Field Medical Excellence Head Turkey, MENA and Africa
Novo Nordisk
Global Project Manager
Novo Nordisk
Global Medical Advisor
Parexel
Corporate VP & WW Head, Real-World Evidence Strategy
Parexel
Principal Consultant, Pricing and Market Access
Parexel
Business Development Director
Pfizer
Senior Director, Group Lead PEH HEOR Patient and Health Impact
Pfizer
Senior Director, Medical Affairs Lead - CV/Metabolism - Emerging Markets
pH Associates
Joint Managing Director
pH Associates
Management Consultant
Pharmamar
International Medical Affairs Manager
PharmaReview
Director
PharmaReview
Scientific Reviewer
Pierre Fabre
Former Senior Director, Medical Affairs - Oncology
Reckitt Benckiser
VP and Head of Medical Affairs and Clinical Research
Roche
Medical and Governmental Affairs Director
Roche Diagnostics
Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics
Senior Medical Affairs Manager
Roche Diagnostics International
International Medical Affairs Manager Women’s Health
Sandoz
Medical Affairs Lead oncology
Sandoz
Head Medical Affairs Europe Biopharmaceuticals and Biosimilars
Sandoz International
Head Global Medical Affairs
Sanofi
Country Medical Chair; Medical Head, Diabetes and Cardiovascular
Sanofi
Medical Lead Consumer Healthcare
Servier
Head of Global Medical Affairs - Internal Medicine & Neuropsychiatry
Servier
Clinical Projects & Data Generation Lead
Servier
Global Medical Manager
SLA Pharma
Medical Director
Succinct Medical Communications
Client Partnerships Lead
Succinct Medical Communications
Account Director
Succinct Medical Communications
Managing Director
Succinct Medical Communications
Account Director
Syneos Health
Project Director, Real World & Late Phase
Syneos Health
Director, Real World & Late Phase
Takeda
Medical Director
Takeda
Medical manager
Takeda
Medical Excellence Manager
Tardis Medical Consultancy
Founding Partner & General Manager
Tardis Medical Consultancy
Capability Development Manager
Techsol Corporation
Director Client Partner - EMEA
Teleflex
Senior Clinical Manager CMA Teleflex
Teleflex Medical
Clinical Manager
Terumo
Medical Science Liaison
Terumo BCT
Senior Manager Medical Affairs, EMEA
Terumo BCT
Medical Affairs Liaison, APAC
Terumo BCT
Medical Science Liaison, EMEA Med Affairs BCS
The EarthWorks (an OPEN Health company)
Patient Service Director
The European Society for Medical Oncology (ESMO)
Medical Oncologist
Truven Health Analytics, IBM Watson Health
Vice President, Europe
Truven Health Analytics, IBM Watson Health
Business Development Director, Key accounts Europe
Veeva Systems
Medical Strategy Director, Europe
Veeva Systems
Director, Global Oncology Strategy
Veeva Systems
Vice President, Global Medical Strategy

Related Videos

Presentation

“Value communication during pathway disruption” : The opportunity and challenge of disruptive medicine including CAR-T & Gene Therapy

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research
Availability: FREE
  • Defining pathway disruption
  • Challenges of value measurement
  • Market Access and Real World Evidence solutions to overcome challenges
Speaker

Amanda Pulfer
Managing Director
PH Associates

Presentation

Real World Evidence Opportunities in Medical Affairs

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research
Availability: FREE
  • Areas of opportunity
  • Main hurdles
  • Elegant method to answer new questions with existing data
  • Methodology – bias and confounding
  • Opportunity for strategic partnership
  • Value for money
Speaker

Torkild Stenbock
General Manager
LINK Medical Research, Norway

Pricing & Registration

3 Day Delegate Pass
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Corporate (Pharma / MedTech / BioTech)
1 Delegate
2,790 EUR
2 Delegates
2,232 EUR
After 20% discount
3 Delegates
1,953 EUR
After 30% discount
4+ Delegates
1,674 EUR
After 40% discount
Solution Provider/Consultant
1 Delegate
2,790 EUR
2 Delegates
2,511 EUR
After 10% discount
3 Delegates
2,371 EUR
After 15% discount
4+ Delegates
2,232 EUR
After 20% discount
Payer/HTA/Regulator
1 Delegate
499 EUR
2 Delegates
499 EUR
3 Delegates
499 EUR
4+ Delegates
499 EUR
Academic
1 Delegate
1,150 EUR
2 Delegates
1,150 EUR
3 Delegates
1,150 EUR
4+ Delegates
1,150 EUR
2 Day Delegate Pass
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Corporate (Pharma / MedTech / BioTech)
1 Delegate
2,290 EUR
2 Delegates
1,832 EUR
After 20% discount
3 Delegates
1,603 EUR
After 30% discount
4+ Delegates
1,374 EUR
After 40% discount
Solution Provider/Consultant
1 Delegate
2,290 EUR
2 Delegates
2,061 EUR
After 10% discount
3 Delegates
1,946 EUR
After 15% discount
4+ Delegates
1,832 EUR
After 20% discount
Academic
1 Delegate
950 EUR
2 Delegates
950 EUR
3 Delegates
950 EUR
4+ Delegates
950 EUR
Payer/HTA/Regulator
1 Delegate
499 EUR
2 Delegates
499 EUR
3 Delegates
499 EUR
4+ Delegates
499 EUR

Upgrade your Attendance to become a Member!

(Only available for corporate registrations)

Upgrade to Silver Member (Add €199 to your current registration) and receive:
  • Video Library Access - Receive a 12 month video library subscription (Access to over 1000 Expert Presentations from our portfolio of events, searchable & viewable on demand with 300 more added annually!
  • Post-Event Reports - Receive 2 x Post event reports (We'll summarize the most important event information for you!) for your topic area!
  • Be recognized at our events for your loyalty.
  • Normally valued at over €1200
Upgrade to Gold Member (Add €999 to your current registration) and receive:
  • Free Event Pass - Attend an additional (one) NextLevel Event (in the 12 month period from your event’s dates). Just inform your NextLevel representative which event!
  • Post-Event Reports - Receive 2 x Post event reports (We'll summarize the most important event information for you!) for your topic area!
  • Video Library Access - Receive a 12 month video library subscription (Access to over 1000 Expert Presentations from our portfolio of events, searchable & viewable on demand with 300+ videos added annually!
  • Live Streaming - Gain access to live streaming and live remote participation, should you be unable to attend an event.
  • Be recognized at our events for your loyalty.
  • Normally valued at over €5000

For more information click here to learn more: https://www.nextlevells.com/membership